SG11201809982RA - Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents - Google Patents

Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents

Info

Publication number
SG11201809982RA
SG11201809982RA SG11201809982RA SG11201809982RA SG11201809982RA SG 11201809982R A SG11201809982R A SG 11201809982RA SG 11201809982R A SG11201809982R A SG 11201809982RA SG 11201809982R A SG11201809982R A SG 11201809982RA SG 11201809982R A SG11201809982R A SG 11201809982RA
Authority
SG
Singapore
Prior art keywords
international
formula
maryland
pct
applicant
Prior art date
Application number
SG11201809982RA
Other languages
English (en)
Inventor
Xiaoyuan Chen
Orit Jacobson Weiss
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of SG11201809982RA publication Critical patent/SG11201809982RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B29/00—Monoazo dyes prepared by diazotising and coupling
    • C09B29/24—Monoazo dyes prepared by diazotising and coupling from coupling components containing both hydroxyl and amino directing groups
    • C09B29/28—Amino naphthols
    • C09B29/30—Amino naphtholsulfonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201809982RA 2016-05-09 2017-05-09 Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents SG11201809982RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333427P 2016-05-09 2016-05-09
PCT/US2017/031696 WO2017196806A1 (en) 2016-05-09 2017-05-09 Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents

Publications (1)

Publication Number Publication Date
SG11201809982RA true SG11201809982RA (en) 2018-12-28

Family

ID=60267260

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809982RA SG11201809982RA (en) 2016-05-09 2017-05-09 Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents

Country Status (6)

Country Link
US (1) US10696631B2 (ja)
EP (1) EP3455206B1 (ja)
JP (1) JP6946342B2 (ja)
CN (1) CN109153641B (ja)
SG (1) SG11201809982RA (ja)
WO (1) WO2017196806A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3310758A1 (en) 2015-06-22 2018-04-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use in the production of long-acting therapeutics
EP3692032B1 (en) 2017-10-03 2024-06-19 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
US20210008232A1 (en) * 2018-02-22 2021-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
TWI745616B (zh) * 2018-09-10 2021-11-11 行政院原子能委員會核能研究所 放射線標誌長效型靶向性胜肽藥物及其生產方法
CN109485642A (zh) * 2018-11-21 2019-03-19 希施生物科技（上海）有限公司 一种制备伊文氏蓝衍生物的方法
SG11202108081PA (en) * 2019-01-30 2021-08-30 The United States Of America As Represented By The Secretary Conjugates of bivalent evans blue dye derivatives and methods of use
WO2020238800A1 (zh) * 2019-05-24 2020-12-03 北京大学 用于肿瘤的靶向放射性药物及其在影像指导下的靶向放射治疗与免疫治疗的联合疗法
CA3174082A1 (en) * 2020-03-04 2021-09-10 Nihon Medi-Physics Co., Ltd. Compound and radioactive labeling compound
CN114790193B (zh) * 2020-12-21 2024-05-10 苏州药明博锐生物科技有限公司 成纤维细胞活化蛋白抑制剂
EP4227300A4 (en) * 2021-02-10 2024-04-24 Yantai Lannacheng Biotechnology Co Ltd ASTRIDGED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, METHOD OF PREPARING THE SAME AND USE THEREOF
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN113004371A (zh) 2021-03-01 2021-06-22 上海蓝纳成生物技术有限公司 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用
CN114796532A (zh) * 2022-04-20 2022-07-29 北京先通国际医药科技股份有限公司 放射性标记的伊文思蓝衍生物药物水溶液及其用途
WO2023236778A1 (zh) * 2022-06-10 2023-12-14 北京大学 一种三功能化合物及其用途
CN115433261B (zh) * 2022-11-07 2023-01-13 烟台蓝纳成生物技术有限公司 一种rgd二聚体化合物及其制备方法和应用
CN115583989B (zh) * 2022-12-09 2023-02-28 烟台蓝纳成生物技术有限公司 一种靶向sstr2的化合物及其制备方法和应用
CN115611779A (zh) * 2022-12-21 2023-01-17 北京先通国际医药科技股份有限公司 一种放射性药物前体的中间体的制备方法及其用途
CN115838393B (zh) * 2023-02-16 2023-05-05 烟台蓝纳成生物技术有限公司 用于fapi合成的中间体及其制备方法和应用
CN115850367B (zh) * 2023-03-02 2023-05-23 北京先通国际医药科技股份有限公司 Psma抑制剂的纯化方法及其用途
CN115947775B (zh) * 2023-03-13 2023-06-09 北京先通国际医药科技股份有限公司 一种制备化合物（i）的方法和化合物（i）及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075925A1 (ja) 2003-02-27 2004-09-10 Kyushu Tlo Company Limited Ｍｒｉ用造影剤
WO2006025304A1 (ja) 2004-08-30 2006-03-09 Kyushu University, National University Corporation 動脈硬化検知用ｍｒｉ造影剤
CN101623504A (zh) * 2008-07-07 2010-01-13 中国人民解放军军事医学科学院放射与辐射医学研究所 伊文思蓝作为实体肿瘤着色剂的用途
CN103242255B (zh) * 2013-04-28 2015-01-14 厦门大学 伊文氏蓝配合物及其制备方法和应用
CN104650217B (zh) * 2015-01-26 2018-08-10 莎穆(上海)生物科技有限公司 伊文氏蓝或其衍生物修饰的Exendin-4及其制备方法和应用
US20160287730A1 (en) 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
EP3310758A1 (en) * 2015-06-22 2018-04-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use in the production of long-acting therapeutics
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
EP3692032B1 (en) 2017-10-03 2024-06-19 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
US20210008232A1 (en) 2018-02-22 2021-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer

Also Published As

Publication number Publication date
EP3455206A4 (en) 2019-11-27
EP3455206B1 (en) 2020-11-04
JP6946342B2 (ja) 2021-10-06
US20190084931A1 (en) 2019-03-21
CN109153641B (zh) 2022-10-18
JP2019519491A (ja) 2019-07-11
EP3455206A1 (en) 2019-03-20
WO2017196806A1 (en) 2017-11-16
CN109153641A (zh) 2019-01-04
US10696631B2 (en) 2020-06-30

Similar Documents

Publication Publication Date Title
SG11201809982RA (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
SG11201811559WA (en) Cancer treatment combinations
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201908650PA (en) Optimized antibody compositions for treatment of ocular disorders
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201808003RA (en) Bromodomain inhibitors
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201900699QA (en) Drug conjugates with self-stabilizing linkers having improved physiochemical properties
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201810561YA (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
SG11201808830YA (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201803915UA (en) Echinomycin formulation, method of making and method of use thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201811712QA (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases